Key result
Candesartan beats lisinopril for renoprotection in cardiorenal syndrome rats but yields slightly less cardioprotection.
Why the study?
Cardiorenal syndrome is a progressive, life-threatening disorder with high morbidity and mortality, prompting an evaluation of the comparative cardio- and reno-protective effects of candesartan and lisinopril.
Does candesartan compared to lisinopril improve cardio- and reno-protective outcomes in a rat model of cardiorenal syndrome type 4?
Does candesartan compared to lisinopril improve cardio- and reno-protective outcomes in a rat model of cardiorenal syndrome type 4?
In a rat model of cardiorenal syndrome type 4, both candesartan and lisinopril provided cardio- and reno-protective effects through attenuation of oxidative stress and inflammation, with candesartan being more reno-protective and lisinopril more cardioprotective.
Answers are grounded in this paper and cite their sources.
Both attenuated cardiorenal injury in this rat model; leaves open differential ARB vs ACEI effects for human cardiorenal syndrome trials.
Cardiorenal syndrome (CRS) is a progressive and life‑threatening disorder associated with high morbidity and mortality. This study aimed to compare the cardio‑ and reno‑protective effects of candesartan and lisinopril in a 5/6 nephrectomy model of type 4 CRS, with emphasis on their modulation of oxidative stress and inflammatory signaling pathways. Immediately after 5/6 subtotal nephrectomy, candesartan (10 mg/kg/day) or lisinopril (12.5 mg/kg/day) was administered by gastric gavage for 10 weeks. Serum urea and creatinine were measured 10 days post‑surgery. At the end of the treatment period, rats were euthanized, and blood, renal, and cardiac tissues were collected. Serum urea, creatinine, and cardiac BNP were quantified, along with renal and cardiac levels of SOD, MDA, NF‑κB, JAK‑2, STAT‑3, and TGF‑β. Histopathological examinations were also performed. Both candesartan and lisinopril significantly improved renal function, reduced arterial blood pressure, attenuated cardiac hypertrophy, lowered BNP levels, decreased renal and cardiac concentrations of MDA, NF‑κB, JAK‑2/STAT‑3, and TGF‑β, and increased SOD levels compared with the 5/6 nephrectomy group. Histopathological examination confirmed marked reductions in renal and cardiac tissue injury. Candesartan exerted greater reno‑protective effects than lisinopril in this model of CRS, whereas lisinopril offered slightly superior cardioprotective benefits. Both agents appear to mediate their therapeutic actions through attenuation of oxidative stress and inflammatory signaling.
No takes yet. Share an insight, caveat, or question.
Eldesouky et al. (2026) studied Cardiorenal syndrome type 4. Candesartan vs. Lisinopril (12.5 mg/kg/day) and untreated 5/6 nephrectomy control was evaluated on Renal and cardiac function, oxidative stress, and inflammatory signaling pathways. Candesartan exerted greater reno-protective effects than lisinopril in a rat model of cardiorenal syndrome, whereas lisinopril offered slightly superior cardioprotective benefits.
Synapse has enriched 10 related papers. Consider them for comparative context: